IMMUPHARMA PLC
Develops novel peptide therapeutics for autoimmune diseases like Lupus (SLE) and CIDP.
IMM | IL
Overview
Corporate Details
- ISIN(s):
- GB0033711010
- LEI:
- 213800VZKGHXC7VUS895
- Country:
- United Kingdom
- Address:
- One, EC1A 7BL London
- Website:
- https://www.immupharma.co.uk/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
ImmuPharma PLC is a specialty biopharmaceutical company focused on the discovery and development of novel peptide-based therapeutics. The company's core research and development efforts target autoimmune diseases, inflammation, and anti-infectives. Its lead asset, P140 (Lupuzor™), is a peptide therapeutic in late-stage clinical development, including a Phase 3 trial for Systemic Lupus Erythematosus (SLE) and a pivotal Phase 2/3 trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). ImmuPharma utilizes proprietary technology to program the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of its compounds to enhance their therapeutic profiles. The company's business model involves advancing its pipeline and creating value through strategic licensing, partnerships, and collaborations for further development and commercialization.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for IMMUPHARMA PLC and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-11 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Exercise of Warrants
|
English | 14.9 KB | |
| 2025-08-20 14:36 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.0 KB | |
| 2025-08-06 08:00 |
Interim Report
Interim Results
|
English | 324.7 KB | |
| 2025-06-12 13:51 |
Post-Annual General Meeting Information
Result of AGM
|
English | 19.8 KB | |
| 2025-05-27 16:13 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.0 KB | |
| 2025-03-14 08:00 |
Regulatory News Service
IMM attending Bio-Europe Spring 17-19 March,Milan
|
English | 15.9 KB | |
| 2025-03-13 08:00 |
Earnings Release
ImmuPharma proves unique Mechanism of Action-P140
|
English | 18.0 KB | |
| 2025-02-21 12:36 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.0 KB | |
| 2025-02-13 08:00 |
Share Issue/Capital Change
£2.91m fundraising; related party transactions
|
English | 56.0 KB | |
| 2025-01-28 13:57 |
Regulatory News Service
Response to Share Price Movement
|
English | 13.9 KB | |
| 2025-01-09 08:00 |
Regulatory News Service
Breakthrough Findings into Autoimmune Diseases
|
English | 18.3 KB | |
| 2025-01-08 08:00 |
Regulatory News Service
IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE
|
English | 14.7 KB | |
| 2024-12-23 08:00 |
Audit Report / Information
Change of Auditor
|
English | 11.2 KB | |
| 2024-12-10 15:36 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.1 KB | |
| 2024-12-04 08:00 |
Board/Management Information
Appointment of Company Secretary
|
English | 14.4 KB |
Automate Your Workflow. Get a real-time feed of all IMMUPHARMA PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for IMMUPHARMA PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
